These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 9856663)

  • 21. Usefulness of strontium-89 for bone pain palliation in metastatic breast cancer patients.
    Fuster D; Herranz D; Vidal-Sicart S; Muñoz M; Conill C; Mateos JJ; Martín F; Pons F
    Nucl Med Commun; 2000 Jul; 21(7):623-6. PubMed ID: 10994664
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Possibilities of systemic radiotherapy with high-purity 89Sr chloride in the treatment of bone metastases].
    Fomin DK; Tararukhina OB; Nazarov AA
    Vestn Rentgenol Radiol; 2012; (2):29-31. PubMed ID: 22730757
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Radionuclide therapy for painful bone metastases. An Italian multicentre observational study. Writing Committee of an Ad Hoc Study Group.
    Piffanelli A; Dafermou A; Giganti M; Colamussi P; Pizzocaro C; Bestagno M;
    Q J Nucl Med; 2001 Mar; 45(1):100-7. PubMed ID: 11456368
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Strontium-89: a desirable therapeutic for bone metastases of prostate cancer].
    Ma YB; Yan WL; Dai JC; Xu F; Yuan Q; Shi HH
    Zhonghua Nan Ke Xue; 2008 Sep; 14(9):819-22. PubMed ID: 18998467
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The use of strontium 89 for palliation of pain from bone metastases associated with hormone-refractory prostate cancer.
    Crawford ED; Kozlowski JM; Debruyne FM; Fair WR; Logothetis CJ; Balmer C; Robinson RG; Porter AT; Kirk D
    Urology; 1994 Oct; 44(4):481-5. PubMed ID: 7524233
    [No Abstract]   [Full Text] [Related]  

  • 26. Effective use of strontium-89 in osseous metastases.
    Kuroda I
    Ann Nucl Med; 2012 Apr; 26(3):197-206. PubMed ID: 22160737
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Palliative treatment of metastasic bone pain].
    Pons F; Fuster D; Vidal-Sicart S
    Rev Esp Med Nucl; 2003 Nov; 22(6):429-38. PubMed ID: 14588238
    [No Abstract]   [Full Text] [Related]  

  • 28. The effect of repeated strontium-89 chloride therapy on bone pain palliation in patients with skeletal cancer metastases.
    Kasalický J; Krajská V
    Eur J Nucl Med; 1998 Oct; 25(10):1362-7. PubMed ID: 9818274
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dose measurement for 89Sr chloride injection.
    Hung JC
    Health Phys; 1995 Apr; 68(4):571. PubMed ID: 7883570
    [No Abstract]   [Full Text] [Related]  

  • 30. Our experience on pain palliation of bone metastasis with Sr-89 or Sm-153 in cancer patients resistant to a conventional analgesic therapy. A retrospective study.
    Montesano T; Giacomobono S; Acqualagna G; Colandrea M; Di Nicola A; Travascio L; Giancamerla M; D'Apollo R; Toteda M; Ugolini F; Filesi M; Ronga G
    Clin Ter; 2009; 160(3):193-9. PubMed ID: 19756320
    [TBL] [Abstract][Full Text] [Related]  

  • 31. 89Sr versus 153Sm-EDTMP: comparison of treatment efficacy of painful bone metastases in prostate and breast carcinoma.
    Baczyk M; Czepczyński R; Milecki P; Pisarek M; Oleksa R; Sowiński J
    Nucl Med Commun; 2007 Apr; 28(4):245-50. PubMed ID: 17325585
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Phase II clinical trial of the radioactive strontium (89Sr) chloride agent, SMS. 2P for pain palliation in patients with prostate cancer with bone metastases].
    Kimura Y; Hamamoto K; Suzuki K; Yokoyama K; Hisada K; Kasagi K; Konishi J; Ichiya Y; Masuda K; Kubo A
    Kaku Igaku; 1995 Mar; 32(3):311-21. PubMed ID: 7537834
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Preliminary application of strontium-89 for the treatment of bone metastases from prostate cancer].
    Zhao W; Deng H; Jie P; Qing C; Zhang X
    Sheng Wu Yi Xue Gong Cheng Xue Za Zhi; 2010 Dec; 27(6):1251-4. PubMed ID: 21374974
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Hypocalcemia associated with strontium-89 administration in a patient with diffuse bone metastases from neuroendocrine carcinoma.
    Mori M; Fadul NA; Bruera E; Dalal S
    J Pain Symptom Manage; 2009 May; 37(5):923-9. PubMed ID: 19041217
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Monitoring and Handing of 89Sr Injection Site Extravasation in a Patient With Breast Cancer.
    Tang J; Fu X; Hu Y; Zhang Y; Shao F
    Clin Nucl Med; 2020 Jul; 45(7):568-569. PubMed ID: 32404705
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Radiopharmaceuticals for the palliation of painful bone metastasis-a systemic review.
    Bauman G; Charette M; Reid R; Sathya J
    Radiother Oncol; 2005 Jun; 75(3):258-70. PubMed ID: 16299924
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Strontium 89 in the treatment of pain due to diffuse osseous metastases: a university hospital experience.
    Ashayeri E; Omogbehin A; Sridhar R; Shankar RA
    J Natl Med Assoc; 2002 Aug; 94(8):706-11. PubMed ID: 12152927
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [The effect of strontium-89 therapy in a patient with cholangiocellular carcinoma].
    Sakai E; Masuda Y; Sato Y; Matsui S; Ota K; Sasaki R; Daisuke M
    Gan To Kagaku Ryoho; 2013 Nov; 40(12):1856-8. PubMed ID: 24393945
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [The role of systemic radiotherapy in the combined treatment for hormone-resistant prostate cancer].
    Solodky VA; Pavlov AY; Panshin GA; Gafanov RA; Fastovets SV; Isaev TK
    Vopr Onkol; 2015; 61(1):31-3. PubMed ID: 26016142
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Use of bone scintigraphy to select patients with multiple myeloma for treatment with strontium-89.
    Edwards GK; Santoro J; Taylor A
    J Nucl Med; 1994 Dec; 35(12):1992-3. PubMed ID: 7989983
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.